<DOC>
	<DOC>NCT00625612</DOC>
	<brief_summary>The purpose of this trial is to evaluate the safety and effectiveness of one dose strength of Denufosol compared to placebo in patients with CF and a predicted FEV1 of greater than or equal to 75% but less than or equal to 110% predicted.</brief_summary>
	<brief_title>Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Have confirmed diagnosis of cystic fibrosis Have FEV1 of greater than or equal to 75% but less than or equal to 110%predicted normal for age, gender and height Be able to reproducibly perform spirometry Be clinically stable for at least 4 weeks before screening Have abnormal renal or liver function Have lung transplant Unable to discontinue use of hypertonic saline Participated in Inspire trial 08108</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>